Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2026-04-27 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Continuation of trading halt 1 page 132.9KB
Capital/Financing Update Classification · 78% confidence The document is an ASX announcement dated 28 April 2026 regarding a continuation of a trading halt pending an announcement on a proposed material capital raising. It refers explicitly to Listing Rule 17.1, pending FDA correspondence and planning of a capital raising. Although it is a trading halt request, the core subject is a forthcoming fundraising activity (capital raise). Therefore, it best fits the “Capital/Financing Update” category (CAP).
2026-04-27 English
Trading Halt 2 pages 193.2KB
Regulatory Filings Classification · 90% confidence The document is an ASX market announcement titled “Trading Halt” requested by Syntara Limited under ASX Listing Rule 17.1. It provides regulatory notification about halting trading pending an announcement, with no financial results, dividends, AGM materials, or management changes. It falls under general regulatory filings as a market announcement. Therefore, it is classified as RNS (Regulatory Filings).
2026-04-26 English
Application for quotation of securities - SNT 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document includes specifics about the securities, issue dates, and the entity's capital structure following the quotation. This type of document is a regulatory announcement related to capital changes but is not a full financial report or earnings release. It fits the category of Share Issue/Capital Change announcements, as it concerns the issuance and quotation of new shares following option exercises.
2026-04-12 English
Notification regarding unquoted securities - SNT 6 pages 19.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Syntara Limited. It includes specifics such as the number of securities issued, dates, and mentions compliance with ASX Listing Rules. The content is a formal announcement of a securities issue rather than a full financial report or detailed analysis. This fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital changes.
2026-04-06 English
NWR Virtual Healthcare Conference Presentation 29 pages 3.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Syntara, dated 25 March 2026, containing forward-looking statements, investment highlights, detailed clinical trial data, drug development pipeline, shareholder information, and management profiles. It includes extensive discussion of Phase 2 clinical trial results for the drug amsulostat, with data on symptom scores, spleen volume reduction, and safety. The content is focused on financial and clinical progress, strategic outlook, and shareholder information, typical of an investor-focused presentation. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. The length (15,000 characters) and detailed content support it being a comprehensive investor presentation rather than a brief announcement or certification. Therefore, the document best fits the category of an Investor Presentation (IP).
2026-03-24 English
Syntara to present at NWR Virtual Healthcare Conference 2 pages 180.9KB
Investor Presentation Classification · 70% confidence The document is a media release announcing that Syntara Limited will present at the NWR Virtual Healthcare Conference on 25 March 2026. It invites shareholders, investors, and interested parties to register for the presentation and mentions that a recording will be available after the live session. The content focuses on the event announcement and company background, with no financial data, report content, or detailed analysis. The document is relatively short (4696 characters) and serves as an announcement rather than a report or transcript. Therefore, it fits best as an Investor Presentation (IP) announcement or related category. However, since it is announcing a presentation event rather than providing the presentation itself or detailed financials, the closest fitting category is Investor Presentation (IP) with moderate confidence.
2026-03-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.